AlphaGrep UK’s Praxis Precision Medicines PRAX Stock Holding History

AlphaGrep UK’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,134	Closed	-$365K	–	907
2026 Q1	$365K	Buy	+1,134	New	+$351K	0.11%	417

Other funds holding PRAX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AlphaGrep UK's PRAX Position: Q2 2026 in Review

AlphaGrep UK sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 1,134 shares — an estimated $365K sold.

AlphaGrep UK first reported a position in PRAX in Q1 2026 and held it in 1 quarter. The position peaked at $365K in Q1 2026. 281 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

AlphaGrep UK reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 1,134 Praxis Precision Medicines shares in Q2 2026, an estimated $365K.
AlphaGrep UK first reported a position in Praxis Precision Medicines in Q1 2026 and held it in 1 quarter.
AlphaGrep UK's Praxis Precision Medicines position peaked at $365K in Q1 2026.
281 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.